Safety and feasibility of intramyocardial injection of autologous CD34+ stem cells were demonstrated in a Phase I/IIa double-blind, randomized controlled trial on 24 RA patients, showing potential bioactivity with improvement in CCS angina class [15]. The gene discussed is CD34; the disease is angina pectoris.